Close menu




December 20th, 2023 | 07:15 CET

Shares for 2024: TUI in travel boom, Pfizer with monster dividend, Almonty Industries receives millions from Germany

  • Mining
  • Tungsten
  • Pharma
  • Biotechnology
  • travel
Photo credits: TUI AG

Three shares from three different sectors and countries: TUI, Pfizer, and Almonty Industries. Are they among the top performers in 2024? At least there are good reasons for a turnaround in all of them. At TUI, the turnaround seems to have already begun. Will it continue? Almonty Industries is facing a decisive year. With the help of Germany's KfW, a massive tungsten mine in South Korea is set to go into operation in 2024. If this succeeds, turnover and profits will likely multiply in the coming years. Like so many Corona winners, Pfizer shares have suffered withdrawal symptoms this year. Will the pharmaceutical giant get back on track in 2024 after hitting a ten-year low? In any case, the dividend yield of 6% is attractive.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: TUI AG NA O.N. | DE000TUAG505 , PFIZER INC. DL-_05 | US7170811035 , ALMONTY INDUSTRIES INC. | CA0203981034

Table of contents:


    Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG
    "[...] China's dominance is one of the reasons why we are so heavily involved in the tungsten market. Here, around 85% of production is in Chinese hands. [...]" Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG

    Full interview

     

    Almonty Industries: Poised for revenue and profit surge

    Will the tide turn for Almonty Industries in 2024? The chances are certainly good. The tungsten producer plans to commission its new flagship mine, Sangdong, next year. It is located in South Korea and is to be developed into one of the world's largest tungsten mines in the coming years. The fact that the German KfW is also co-financing the development underscores the importance of tungsten for Western industrialized nations. It is not without reason that it is one of the critical metals, as it is used in the production of batteries in medical technology and aviation, among other industries. Just a few weeks ago, KfW disbursed a further tranche of the loan in the amount of USD 13.7 million. Almonty has now received USD 53.9 million of the total USD 75.1 million and can enter the final phase at Sangdong. It is worth noting that the Company is already mining tungsten in Spain and Portugal.

    Analysts are correspondingly confident about Almonty's sales and earnings performance in the coming years. Sphene Capital expects turnover to climb from CAD 28.9 million in the current year to around CAD 100 million by 2025. According to the experts' estimates, Almonty will close the current year with a negative EBITDA for the last time. A minus of CAD 3 million is estimated. After a positive EBITDA of CAD 20 million in the coming year, this figure is expected to reach CAD 45 million in 2025. The after-tax profit is then expected to be CAD 24.5 million. With a market capitalization of around CAD 120 million, the share appears to be anything but expensive.

    TUI: Travel boom continues

    The TUI share has been one of the surprises of recent weeks. It has gained around 50% in value since its low of EUR 4.61 at the end of October. However, it would still need to climb more than 50% just to reach the yearly high of EUR 11.44, not to mention the pre-COVID level of over EUR 30.

    Operationally, things are going well. With the preliminary figures for the past financial year 2022/23, the tourism group reported an increase in sales of EUR 4.12 billion to EUR 20.67 billion. Adjusted EBIT more than doubled from EUR 409 million to EUR 977 million. One reason for the fall in the share price in the current year was the high level of debt. TUI is making progress in reducing this. A decline in net debt (in accordance with IFRS 16) from EUR -3.43 billion to EUR -2.1 billion was reported.

    Last week, the summer program for 2024 was presented. It is the most critical time of the year for the tourism group. And early bookings for the coming summer are already expected to be 25% up on the previous year. According to the report, customers are booking traditional vacation destinations such as Mallorca and Antalya and Greek islands such as Crete and Rhodes as top travel destinations. However, long-haul trips like the USA or the Maldives are also trendy. The early booking campaign runs until February 28, 2024.

    While some analysts are still cautious about the TUI share, Deutsche Bank recommends it as a "Buy". The analysts are confident that the positive business development will continue. They have raised their price target slightly from EUR 10 to EUR 10.50.

    Pfizer: High dividend and share price at ten-year low

    Pfizer shareholders needed strong nerves this year. The share price almost halved and is currently trading at around EUR 25. Falling sales of BioNTech's COVID-19 vaccine caused some disgruntlement. The pharmaceutical giant has invested the high profits of recent years in takeovers - how these pay off will probably determine the share price performance in the coming year. Two analysts have recently recommended the Pfizer share as a "Buy". One of them being DZ Bank. Although the Group's recently published forecast was initially disappointing, the analysts still see opportunities for sales and earnings to exceed the low market expectations. The DZ Bank price target for the Pfizer share is USD 33.

    With a target price of USD 32, Jefferies is at a similar level. Their analysts were also disappointed by Pfizer's forecasts for 2024. Nevertheless, they recommend the share as a "Buy". The share could have bottomed out at the current ten-year low, and the dividend yield is now 6%.


    One year's losers are often among next year's top performers. All three stocks presented have the potential to perform well in 2024. Almonty is still a small cap, but with the commissioning of Sangdong, it could move into a new league - in terms of turnover, profit and market capitalization. Things are also looking good for TUI at the moment. The numerous early bookings - despite Germany's difficult overall economic situation - point to a successful 2024. At Pfizer, the high dividend is attractive, but the takeovers must bear fruit.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Armin Schulz on February 21st, 2024 | 07:30 CET

    Barrick Gold, Desert Gold, Renk - Golden times everywhere?

    • Mining
    • Gold
    • Defense

    The world is full of economic uncertainty and geopolitical tensions. These are ideal conditions for gold, which is still considered a safe haven. There are now several factors that point to a sustained upswing in gold prices. One factor is the increased involvement of central banks, which are increasing their reserves to an extent not seen for decades. Another factor is the discussion within the BRICS nations about introducing a new currency backed by gold as a counterweight to the dominant US dollar. Therefore, today, we look at two gold companies and shed light on Renk, a representative of the defense industry, which is also experiencing golden times.

    Read

    Commented by Juliane Zielonka on February 21st, 2024 | 07:15 CET

    Saturn Oil + Gas, Plug Power, Deutsche Pfandbriefbank - Energy shares and falling knives - where is it worth getting in?

    • Mining
    • Oil
    • Hydrogen
    • greenhydrogen
    • Banking

    The Canadian company Saturn Oil & Gas has announced its capital and operating budget plans for 2024. The main focus is on sustainable oil and gas production with high capital returns, a structured capital allocation and continuous rapid debt repayment. Plug Power is also gaining momentum and taking strong cost-saving measures to maintain its position at the forefront as a green hydrogen provider. Deutsche Pfandbriefbank (pbb) came under the spotlight last week as investors dumped shares due to its involvement in the US office real estate market. Is this bank a falling knife, or does this week offer a potential entry point? We provide the background.

    Read

    Commented by Fabian Lorenz on February 21st, 2024 | 07:00 CET

    Top news: BYD, Bayer and Globex Mining

    • Mining
    • Gold
    • Commodities
    • Electromobility
    • chemicals

    Bayer shocked investors yesterday with the announcement of its dividend cut, which shouldn't have been much of a surprise. The Company is burdened with high debt, endless legal fines, and an empty pharmaceutical pipeline. In an initial reaction, analysts have lowered the share price target. BYD, on the other hand, is doing well operationally. Only the share price is not picking up. Will a share buyback turn the share price around? For those who want to profit from the commodity boom with reduced risk, then Globex Mining's stock is attractive. The news flow is strong, and those who act quickly can still register and follow the live presentation of the mining incubator at the 10th International Investment Forum, IIF, today.

    Read